{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:13:31Z","timestamp":1768403611468,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40487-019-00102-3","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:43:06Z","timestamp":1576507386000},"page":"161-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-0590","authenticated-orcid":false,"given":"Riccardo","family":"Giampieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Maccaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Sotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Baleani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Meletani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bittoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Mentrasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"issue":"21","key":"102_CR1","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"LS Schwartzberg","year":"2014","unstructured":"Schwartzberg LS, Rivera F, Karthaus M, et al. A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"102_CR2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25(7):1346\u201355. https:\/\/doi.org\/10.1093\/annonc\/mdu141. Epub 2014 Apr 8.","journal-title":"Ann Oncol"},{"issue":"6","key":"102_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/bjc.2015.299","volume":"113","author":"A Stein","year":"2015","unstructured":"Stein A, Atanackovic D, Hildebrandt B, et al. Upfront FOLFOXIRI\u2009+\u2009bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer. 2015;113(6):872\u20137. https:\/\/doi.org\/10.1038\/bjc.2015.299. Epub 2015 Sep 3.","journal-title":"Br J Cancer"},{"issue":"13","key":"102_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9. Epub 2015 Aug 31.","journal-title":"Lancet Oncol"},{"issue":"1","key":"102_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, et al. Upper gastrointestinal clinical studies group of the national cancer research institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa073149.","journal-title":"N Engl J Med"},{"issue":"19","key":"102_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"3","key":"102_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.pain.2009.03.024","volume":"144","author":"N Attal","year":"2009","unstructured":"Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144(3):245\u201352. https:\/\/doi.org\/10.1016\/j.pain.2009.03.024. Epub 2009 May 19.","journal-title":"Pain"},{"key":"102_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","volume":"406","author":"H Adelsberger","year":"2000","unstructured":"Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406:25\u201332.","journal-title":"Eur J Pharmacol"},{"key":"102_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/sj.bjp.0706407","volume":"146","author":"RG Webster","year":"2005","unstructured":"Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005;146:1027\u201339.","journal-title":"Br J Pharmacol"},{"key":"102_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.taap.2018.01.001","volume":"340","author":"AF Pereira","year":"2018","unstructured":"Pereira AF, de Oliveira FFB, de Freitas Alves BW, et al. Neurotoxic effect of oxaliplatin: comparison with its oxalate-free analogue cis-[PtII(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)] (LLC-1402) in mice. Toxicol Appl Pharmacol. 2018;340:77\u201384. https:\/\/doi.org\/10.1016\/j.taap.2018.01.001. Epub 2018 Jan 4.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1\u20133","key":"102_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.pain.2009.09.003","volume":"147","author":"M Sakurai","year":"2009","unstructured":"Sakurai M, Egashira N, Kawashiri T, et al. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009;147(1\u20133):165\u201374. https:\/\/doi.org\/10.1016\/j.pain.2009.09.003. Epub 2009 Sep 25.","journal-title":"Pain"},{"issue":"1","key":"102_CR12","first-page":"71","volume":"41","author":"S Eto","year":"2014","unstructured":"Eto S, Yamamoto K, Shimazu K, et al. Formation of oxalate in oxaliplatin injection diluted with infusion solutions. Gan To Kagaku Ryoho. 2014;41(1):71\u20135 (in Japanese).","journal-title":"Gan To Kagaku Ryoho"},{"issue":"32","key":"102_CR13","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","volume":"33","author":"HJ Schmoll","year":"2015","unstructured":"Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. 2015;33(32):3733\u201340. https:\/\/doi.org\/10.1200\/JCO.2015.60.9107. Epub 2015 Aug 31.","journal-title":"J Clin Oncol"},{"issue":"5","key":"102_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/emmm.201100134","volume":"3","author":"J Descoeur","year":"2011","unstructured":"Descoeur J, Pereira V, Pizzoccaro A, et al. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med. 2011;3(5):266\u201378. https:\/\/doi.org\/10.1002\/emmm.201100134. Epub 2011 Mar 24.","journal-title":"EMBO Mol Med"},{"issue":"4","key":"102_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3892\/etm.2014.1534","volume":"7","author":"E Usami","year":"2014","unstructured":"Usami E, Kimura M, Kanematsu T, et al. Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B. Exp Ther Med. 2014;7(4):941\u20136.","journal-title":"Exp Ther Med."},{"issue":"2","key":"102_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clinthera.2017.12.006","volume":"40","author":"N Okada","year":"2018","unstructured":"Okada N, Azuma M, Imanishi M, et al. Potential usefulness of early potassium supplementation for preventing severe hypokalemia induced by liposomal amphotericin B in hematologic patients: a retrospective study. Clin Ther. 2018;40(2):252\u201360. https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.006. Epub 2018 Jan 2.","journal-title":"Clin Ther"},{"key":"102_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32462","author":"RL Jones","year":"2019","unstructured":"Jones RL, Maki RG, Patel SR, et al. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: clinical considerations for outpatient administration of trabectedin. Cancer. 2019. https:\/\/doi.org\/10.1002\/cncr.32462. Epub ahead of print.","journal-title":"Cancer"},{"key":"102_CR18","doi-asserted-by":"publisher","first-page":"673019","DOI":"10.1155\/2012\/673019","volume":"2012","author":"AP Kotsia","year":"2012","unstructured":"Kotsia AP, Dimitriadis G, Baltogiannis GG, Kolettis TM. Torsade de pointes and persistent QTc prolongation after intravenous amiodarone. Case Rep Med. 2012;2012:673019. https:\/\/doi.org\/10.1155\/2012\/673019. Epub 2012 Mar 5.","journal-title":"Case Rep Med"},{"issue":"2","key":"102_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3978\/j.issn.2078-6891.2010.024","volume":"1","author":"T Kono","year":"2010","unstructured":"Kono T, Satomi M, Asama T, et al. Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. J Gastrointest Oncol. 2010;1(2):97\u2013101. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2010.024.","journal-title":"J Gastrointest Oncol"},{"key":"102_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1752-1947-4-36","volume":"4","author":"MH Tan","year":"2010","unstructured":"Tan MH, Chay WY, Ng JH, et al. Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report. J Med Case Rep. 2010;4:36. https:\/\/doi.org\/10.1186\/1752-1947-4-36.","journal-title":"J Med Case Rep"},{"issue":"7","key":"102_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00228-008-0474-x","volume":"64","author":"M Basso","year":"2008","unstructured":"Basso M, Cassano A, Modoni A, et al. A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur J Clin Pharmacol. 2008;64(7):739\u201341. https:\/\/doi.org\/10.1007\/s00228-008-0474-x. Epub 2008 Mar 19.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"102_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000380849","volume":"2015","author":"M Chandar","year":"2015","unstructured":"Chandar M, De Wilton R. Severe generalized weakness, paralysis, and aphasia following administration of irinotecan and oxaliplatin during FOLFIRINOX chemotherapy. Case Rep Oncol. 2015;2015(8):138\u201341. https:\/\/doi.org\/10.1159\/000380849.","journal-title":"Case Rep Oncol"},{"key":"102_CR23","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1007\/s12032-012-0264-2","volume":"29","author":"E Krexner","year":"2012","unstructured":"Krexner E, Stickler A, Prainer C, Finsterer J. Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion. Med Oncol. 2012;29:3592\u20133. https:\/\/doi.org\/10.1007\/s12032-012-0264-2.","journal-title":"Med Oncol"},{"issue":"4","key":"102_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","volume":"29","author":"A Grothey","year":"2011","unstructured":"Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: nCCTG N04C7. J Clin Oncol. 2011;29(4):421\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.31.5911. Epub 2010 Dec 28.","journal-title":"J Clin Oncol"},{"issue":"10","key":"102_CR25","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","volume":"32","author":"CL Loprinzi","year":"2014","unstructured":"Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol. 2014;32(10):997\u20131005. https:\/\/doi.org\/10.1200\/JCO.2013.52.0536. Epub 2013 Dec 2.","journal-title":"J Clin Oncol"},{"key":"102_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","volume":"80","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Caroen S, Oronsky A, et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017;80:895\u2013907. https:\/\/doi.org\/10.1007\/s00280-017-3392-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"102_CR27","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/JCO.2014.58.85330","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.58.85330. Epub 2015 Aug 17.","journal-title":"J Clin Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-019-00102-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-019-00102-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-019-00102-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:01:09Z","timestamp":1724457669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-019-00102-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1007\/s40487-019-00102-3","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}